secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2026-10-06T13:14:18+00:00
Accession:  0001193125-26-415015
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Repligen closes BioLife Solutions buy for $11.25 cash plus 0.1442 RGEN shares per share
--------------------------------------------------------------------------------

- BioLife stockholders received $11.25 in cash plus 0.1442 shares of Repligen common stock per share, with cash in lieu of fractional shares.
- Mergers closed October 6, 2026 under the July 21, 2026 agreement; BioLife ceased to exist as a separate legal entity and became a Repligen subsidiary.
- BioLife Common Stock is being delisted from Nasdaq via Form 25, with a Form 15 planned to suspend reporting obligations under Sections 13 and 15(d).
- BioLife's CryoStor-led biopreservation media serves 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.
- Repligen says the deal adds a high-margin consumables franchise with recurring revenue and Asia Pacific reach; 2026 outlook impact to be detailed on the Q3 2026 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/0001193125-26-415015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312526415015/d240327d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-415015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer